Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C162995> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- NCIT_C162995 IAO_0000115 "The monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation." @default.
- NCIT_C162995 NCIT_A32 NCIT_C1909 @default.
- NCIT_C162995 NCIT_NHC0 "C162995" @default.
- NCIT_C162995 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C162995 NCIT_P107 "Fedratinib Hydrochloride" @default.
- NCIT_C162995 NCIT_P108 "Fedratinib Hydrochloride" @default.
- NCIT_C162995 NCIT_P208 "CL973405" @default.
- NCIT_C162995 NCIT_P210 "1374744-69-0" @default.
- NCIT_C162995 NCIT_P302 "intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)." @default.
- NCIT_C162995 NCIT_P319 "UH9J2HBQWJ" @default.
- NCIT_C162995 NCIT_P322 "CTRP" @default.
- NCIT_C162995 NCIT_P322 "FDA" @default.
- NCIT_C162995 NCIT_P322 "GDC" @default.
- NCIT_C162995 NCIT_P329 "657793" @default.
- NCIT_C162995 NCIT_P330 "657793" @default.
- NCIT_C162995 NCIT_P375 "Fedratinib Hydrochloride" @default.
- NCIT_C162995 NCIT_P399 "657793" @default.
- NCIT_C162995 normalizedInformationContent "100" @default.
- NCIT_C162995 referenceCount "1" @default.
- NCIT_C162995 hasExactSynonym "Benzenesulfonamide, N-(1,1-Dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:1)" @default.
- NCIT_C162995 hasExactSynonym "FEDRATINIB HYDROCHLORIDE" @default.
- NCIT_C162995 hasExactSynonym "Fedratinib Dihydrochloride Monohydrate" @default.
- NCIT_C162995 hasExactSynonym "Fedratinib Hydrochloride" @default.
- NCIT_C162995 hasExactSynonym "Inrebic" @default.
- NCIT_C162995 hasExactSynonym "N-tert-butyl-3-((5-methyl-2-((4-(2-pyrrolidin-1-ylethoxy)phenyl)amino)pyrimidin-4-yl)amino) Benzenesulfonamide Dihydrochloride Monohydrate" @default.
- NCIT_C162995 hasExactSynonym "SAR302503a" @default.
- NCIT_C162995 inSubset NCIT_C116977 @default.
- NCIT_C162995 inSubset NCIT_C116978 @default.
- NCIT_C162995 inSubset NCIT_C128784 @default.
- NCIT_C162995 inSubset NCIT_C157711 @default.
- NCIT_C162995 inSubset NCIT_C157712 @default.
- NCIT_C162995 inSubset NCIT_C176424 @default.
- NCIT_C162995 inSubset NCIT_C177537 @default.
- NCIT_C162995 inSubset NCIT_C63923 @default.
- NCIT_C162995 type Class @default.
- NCIT_C162995 isDefinedBy ncit.owl @default.
- NCIT_C162995 label "Fedratinib Hydrochloride" @default.
- NCIT_C162995 subClassOf NCIT_C125450 @default.
- NCIT_C162995 subClassOf NCIT_C129824 @default.
- NCIT_C162995 subClassOf NCIT_C129825 @default.
- NCIT_C162995 subClassOf NCIT_C1404 @default.
- NCIT_C162995 subClassOf NCIT_C162995 @default.
- NCIT_C162995 subClassOf NCIT_C163758 @default.
- NCIT_C162995 subClassOf NCIT_C172200 @default.
- NCIT_C162995 subClassOf NCIT_C1908 @default.
- NCIT_C162995 subClassOf NCIT_C1909 @default.
- NCIT_C162995 subClassOf NCIT_C1967 @default.
- NCIT_C162995 subClassOf NCIT_C2189 @default.
- NCIT_C162995 subClassOf NCIT_C274 @default.
- NCIT_C162995 subClassOf NCIT_C471 @default.